Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy-Reference-Cited by-同舟云学术

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

Published:2017-02-21 Issue:1 Volume:5 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Shiuan Eileen,Beckermann Kathryn E.,Ozgun Alpaslan,Kelly Ciara,McKean Meredith,McQuade Jennifer,Thompson Mary Ann,Puzanov Igor,Greer John P.,Rapisuwon Suthee,Postow Michael,Davies Michael A.,Eroglu Zeynep,Johnson Douglas

Funder

National Institutes of Health

Cancer Research Institute

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-017-0210-0.pdf

Reference23 articles.

1. Chen L, Han X. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384–91.

2. Wolchok JD. PD-1 blockers. Cell. 2015;162:937.

3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34.

4. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018–28.

5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in advanced Melanoma. N Engl J Med. 2015;372:2521–32.

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia;Investigational New Drugs;2024-09-12

2. Platelet PD-L1 inhibits storage-induced apoptosis by sustaining activation of the AKT signalling pathway;Thrombosis Research;2024-08

3. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update;Journal for ImmunoTherapy of Cancer;2024-07

4. Difficulties in differential diagnosis of hematological toxicity during therapy with immune checkpoint inhibitors;Clinical Case in Oncology;2024-06-21

5. Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports;Cancers;2024-05-16